Skip to main content

Table 2 Multivariate survival analysis

From: DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

   Multivariate
Covariate Baseline Coefficient(bi) HR(exp(bi) 95,0% CI for Exp(B) p-value
Grade 2 Grade1 1,67 5,30 (0,52-53,75) 0,159
Grade 3 Grade1 3,45 31,65 (2,47-404,27) 0,008
ER ER positive 2,59 13,39 (2,62-68,50) 0,002
TP53 TP53 wild type 1,75 5,73 (1,11-29,40) 0,036
Stage 3 Stage2 0,19 1,21 (0,20-7,03) 0,833
Stage 4 Stage2 2,00 7,38 (1,12-48,55) 0,038
ABCB1 _2 Methylated ABCB1 _2 -1,13 0,32 (0,05-2,20) 0,247
FOXC1 _3 Methylated FOXC1 _3 1,99 7,32 (1,11-48,31) 0,039
GSTP1 _2 Methylated GSTP1 _2 2,02 7,52 (1,76-32,07) 0,006
  1. Multivariate survival analysis using the Cox regression model using the categorical methylation data. Positive hazard ratios indicate an increased risk of dying from breast cancer and are calculated for the different covariates in reference to the baseline as given in the 2nd column.